Research
Hormonal
SGLT2 inhibitors reduce cardiovascular mortality and heart failure hospitalization in insulin-resistant patients by promoting ketone body production and reducing sympathetic overdrive.
If you have Type 2 Diabetes and heart issues, ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga). They are proven to protect your heart and reduce hospital stays, not just lower blood sugar. The benefit comes from how they change your heart's energy use and stress levels.
GoodSupportsHIGH confidence
Notably, SGLT2 inhibitors, GLP-1 receptor agonists, and metformin show potential reductions in cardiovascular mortality and heart failure hospitalization (HHF) through mechanisms such as reducing fibrosis, inflammation, and oxidative stress... Finally, these drugs also increase the production of ketone bodies, which serve as an alternative energy source for the heart... empagliflozin was found to reduce sympathetic overdrive (i.e., catecholamine levels), a factor in neurohormonal activation and a key indicator of adverse cardiac remodeling
Why this rating
Based on a review of multiple clinical trials and meta-analyses cited in the text.
Source
Advances in the Insulin–Heart Axis: Current Therapies and Future Directions
Alfredo Caturano et al. · International Journal of Molecular Sciences · 2024
DOI 10.3390/ijms251810173
narrative_reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modifications, specifically Mediterranean diet and moderate aerobic exercise, are the cornerstone for managing insulin resistance and improving cardiovascular outcomes.Strong
- GLP-1 receptor agonists reduce major adverse cardiac events and cardiovascular mortality in patients with Type 2 Diabetes, particularly those without pre-existing heart failure.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →